Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...